MedTrace Logo

SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)

NCT05182697 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-05-16

No results posted yet for this study

Summary

To evaluate the safety and efficacy of SCI-210 in the treatment of Autism Spectrum Disorders (ASD)

Conditions

  • Autism Spectrum Disorder (ASD)

Interventions

DRUG

SCI-210

Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily

DRUG

Oral CBD oil

CBD- active CBD oil with twice daily CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.

Sponsors & Collaborators

  • Negev Autism Center Soroka University Medical Center

    collaborator UNKNOWN

  • SciSparc

    lead INDUSTRY

Principal Investigators

  • Gal Meiri, MD, MHA · Clinical Research Center and Negev Autism Center Soroka University Medical Center, Be'er-Sheva, Israel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-21
Primary Completion
2026-05-31
Completion
2026-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05182697 on ClinicalTrials.gov